Trial Profile
Phase 1/2 Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 May 2021
Price :
$35
*
At a glance
- Drugs Sonidegib (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 03 Jun 2019 Status changed from active, no longer recruiting to discontinued.
- 23 Apr 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Dec 2018.
- 05 Oct 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Jan 2018.